Clinical Management of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative condition marked by the loss of upper and lower motor neurons, resulting in muscle weakness, respiratory compromise and eventual paralysis. Clinical management aims to slow disease progression, maintain function and maximise quality of life through a coordinated multidisciplinary team. Approved pharmacological agents such as riluzole and edaravone offer modest survival benefits, while symptomatic therapies address spasticity, sialorrhoea and pain. Respiratory insufficiency is managed with non-invasive ventilation and, when necessary, invasive ventilatory support. Nutritional status is preserved via percutaneous gastrostomy once swallowing becomes unsafe, and communication is facilitated through augmentative and alternative communication devices. Regular assessment with standardised functional scales guides intervention timing and informs prognostic discussions. Emerging approaches include digital health platforms for remote monitoring, personalised prognostic algorithms and early integration of palliative care to address psychosocial needs and caregiver support on a global scale.

Research from Nature Portfolio

Recent studies have evaluated home-based wearable sensors paired with machine learning algorithms to track motor decline in ALS. In a large cohort, individuals wore accelerometers on all four limbs during natural daily activities. Passively collected movement data were analysed to generate limb-specific severity scores that progressed more rapidly than scores from the established functional rating scale. This increased sensitivity suggests that such digital measures could reduce clinical trial sample sizes and provide objective, continuous monitoring in both research and routine care settings.

Clinical Management of Amyotrophic Lateral Sclerosis publication trend

The graph below shows the total number of articles in clinical management of amyotrophic lateral sclerosis across all publications each year (not limited to Nature Index journals).

Technical terms

Bulbar dysfunction: Impairment of speech and swallowing due to degeneration of cranial nerve motor neurons.

Gastrostomy: Placement of a feeding tube through the abdominal wall into the stomach to ensure adequate nutrition.

ALS Functional Rating Scale-Revised (ALSFRS-R): A clinician-rated instrument measuring functional abilities in ALS across speech, swallowing, mobility and respiratory domains.

Machine-learned severity score: A quantitative metric derived from algorithmic analysis of sensor data to estimate disease progression objectively.

Multidisciplinary team: A coordinated group of health-care professionals from neurology, respiratory medicine, nutrition, speech and language therapy, and palliative care providing holistic ALS management.

References

1. Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures. npj Digital Medicine (2023).
2. At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis. Nature Communications (2023).
3. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. The Lancet Neurology (2015).
4. Clinical Measures of Bulbar Dysfunction in ALS. Frontiers in Neurology (2019).
5. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. Journal of Neurology (2015).